ABMC Phone: 800-227-1243

518-758-8158

Drug Tests 100% Manufactured in the USA

ABMC Reports Third Quarter 2011 Results

KINDERHOOK, N.Y. - November 14, 2011 - American Bio Medica Corporation (ABMC.PK) today announced financial results for the three and nine months ended September 30, 2011.

Net sales for the third quarter of 2011 were $2,365,000, compared to $2,530,000 for the third quarter of 2010, representing a decrease of $165,000, or 6.5%. For the nine months ended September 30, 2011, net sales were $6,898,000, compared to $8,082,000 for the nine months ended September 30, 2010, representing a decrease of $1,184,000, or 14.6%.

The Company reported an operating income of $26,000 in the third quarter of 2011, compared to an operating loss of $247,000 in the third quarter of 2010. Net loss for the third quarter of 2011 was $28,000, or $(0.00) per share, compared to a net loss of $300,000, or $(0.01) per share in the third quarter of 2010. Operating loss for the nine months ended September 30, 2011 was $173,000, compared to an operating loss of $244,000 in the nine months ended September 30, 2010. Net loss for the nine months ended September 30, 2011 was $330,000, or $(0.02) per share, compared to a net loss of $408,000, or $(0.02) per share in the nine months ended September 30, 2010.

ABMC Chief Executive Officer Stan Cipkowski stated, "Even with the decline in sales in the third quarter, we were able to make a small profit from operations as a result of our expense reductions. We remain hopeful that new sales opportunities will offset sales declines we are experiencing as a result of an uncertain economy."

For more information on ABMC or its drug testing products, please visit www.abmc.com.

About American Bio Medica Corporation

American Bio Medica Corporation is a biotechnology company that develops, manufactures and markets accurate, cost-effective immunoassay test kits, including some of the world's most effective point of collection tests for drugs of abuse. The Company and its worldwide distribution network target the workplace, government, corrections, clinical and educational markets. ABMC's Rapid Drug Screen®, Rapid ONE®, RDS® InCup®, Rapid TOX® and Rapid TOX Cup® II test for the presence or absence of drugs of abuse in urine, while OralStat® and Rapid STAT™ tests for the presence or absence of drugs of abuse in oral fluids. ABMC's Rapid Reader® is a compact, portable device that, when connected to any computer, interprets the results of an ABMC drug screen, and sends the results to a data management system, enabling the test administrator to easily manage their drug testing program.

This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, risks and uncertainties related to the following: continued acceptance of our products, increased levels of competition in our industry, acceptance of new products, product development, compliance with regulatory requirements, intellectual property rights, our dependence on key personnel, third party sales and suppliers, trading in our common shares may be subject to "penny stock" rules, our history of recurring net losses and our ability to continue as a going concern. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results. Investors are strongly encouraged to review the section entitled "Risk Factors" in the Company's annual report on Form 10-K for the fiscal year ended December 31, 2010, quarterly reports on Form 10-Q, and other periodic reports on file with the Securities and Exchange Commission for a discussion of risks and uncertainties that could affect operating results and the market price of the Company's common shares.

AMERICAN BIO MEDICA CORPORATION
Statements of Operations
(in thousands, except loss per share and shares outstanding)
(unaudited)
For the three For the three For the nine For the nine
months ended months ended months ended months ended
September 30, 2011 September 30, 2010 September 30, 2011 September 30, 2010
Net sales $ 2,365 $ 2,530 $ 6,898 $ 8,082
Cost of goods sold 1,399 1,653 4,019 4,793
Gross profit 966 877 2,879 3,289
Operating expenses:
Research and development 61 28 170 244
Selling and marketing 417 511 1,319 1,532
General and administrative 462 585 1,563 1,757
Total operating expenses 940 1,124 3,052 3,533
Operating income / (loss) 26 (247) (173) (244)
Other expense (49) (52) (151) (160)
Net loss before tax (23) (299) (324) (404)
Income tax expense (5) (1) (6) (4)
Net loss $ (28) $ (300) $ (330) $ (408)
Basic & diluted loss per common share $ (0.00) $ (0.01) $ (0.02) $ (0.02)
Weighted average shares outstanding – basic and diluted
21,744,768
21,744,768
21,744,768
21,744,768


American Bio Medica Corporation
Balance Sheets
(in thousands)
September 30,
December 31,
2011
(unaudited)
2010
ASSETS
Current Assets
Cash and cash equivalents $ 22 $ 37
Accounts receivable, net of allowance for doubtful accounts of $66,000 at September 30, 2011 and $76,000 at December 31, 2010
1,138
743
Inventory, net of allowance for slow moving and obsolete inventory of $207,000 at September 30, 2011 and $213,000 at December 31, 2010

3,176

3,604

Prepaid expenses and other current assets 149 121
Total current assets 4,485 4,505
Property, plant and equipment, net 1,341 1,409
Debt issuance costs, net 37 72
Other assets 29 29
Total assets $ 5,892 $ 6,015
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities
Accounts payable 684 432
Accrued expenses and other current liabilities 224 287
Wages payable 288 252
Line of credit 520 493
Current portion of long-term debt and unearned grant 889 140
Total current liabilities 2,605 1,604
Other liabilities 142 140
Long-term debt 639 1,480
Related party note 124 124
Unearned grant 10 10
Total liabilities 3,520 3,358
COMMITMENTS AND CONTINGENCIES
Stockholders’ Equity:
Common stock 217 217
Additional paid-in capital 19,374 19,328
Accumulated deficit (17,219) (16,888)
Total stockholders’ equity 2,372 2,657
Total liabilities and stockholders’ equity $ 5,892 $ 6,015

Contact:
American Bio Medica Corporation
Stan Cipkowski, 800-227-1243, Ext 106
Chief Executive Officer